The effect of Bromelain and Montelukast in Covid-19 patients

The effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150725023332N3

Enrollment

Registered

2020-06-27

Start date

2020-04-20

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-COV-2. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: In group 1, an Anaheal capsule (Parmon Amin Health Company) containing 200 mg of Bromelain was given to patients every 8 hours (one hour before or after a meal). In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Infection with coronavirus is new

Exclusion criteria

Exclusion criteria: History of severe liver disease History of severe respiratory disorders BMI <12

Design outcomes

Primary

Measure	Time frame
Changes in lymphocyte levels. Timepoint: Before intervention , 1 hour later, 6 hours later and 12 hours after the intervention. Method of measurement: Biochemical and immunological tests.;CRP. Timepoint: Before intervention , 1 hour later, 6 hours later and 12 hours after the intervention. Method of measurement: Biochemical test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Jahangirifard

Shahid Beheshti University of Medical Sciences

alirezajahangiri@sbmu.ac.ir+98 21 2610 5050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026